BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20845477)

  • 21. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.
    Dong X; Jiao L; Li Y; Evans DB; Wang H; Hess KR; Abbruzzese JL; Li D
    J Clin Oncol; 2009 Apr; 27(10):1592-9. PubMed ID: 19237629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma.
    Horowitz DP; Hsu CC; Wang J; Makary MA; Winter JM; Robinson R; Schulick RD; Cameron JL; Pawlik TM; Herman JM
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1391-7. PubMed ID: 20643511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.
    Golcher H; Brunner T; Grabenbauer G; Merkel S; Papadopoulos T; Hohenberger W; Meyer T
    Eur J Surg Oncol; 2008 Jul; 34(7):756-64. PubMed ID: 18191528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic variants in glucose-6-phosphate isomerase gene as prognosis predictors in hepatocellular carcinoma.
    Lyu Z; Chen Y; Guo X; Zhou F; Yan Z; Xing J; An J; Zhang H
    Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):698-704. PubMed ID: 27288297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
    Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
    J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PKM2 Promotes Cell Survival and Invasion Under Metabolic Stress by Enhancing Warburg Effect in Pancreatic Ductal Adenocarcinoma.
    Li C; Zhao Z; Zhou Z; Liu R
    Dig Dis Sci; 2016 Mar; 61(3):767-73. PubMed ID: 26500118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer.
    Wang L; Miao X; Tan W; Lu X; Zhao P; Zhao X; Shan Y; Li H; Lin D
    Clin Gastroenterol Hepatol; 2005 Aug; 3(8):743-51. PubMed ID: 16234002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk.
    Jiao L; Hassan MM; Bondy ML; Abbruzzese JL; Evans DB; Li D
    Cancer Lett; 2007 Jan; 245(1-2):61-8. PubMed ID: 16458430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
    Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
    Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma.
    Stracquadanio G; Vrugt B; Flury R; Schraml P; Würl P; Müller TH; Knippschild U; Henne-Bruns D; Breitenstein S; Clavien PA; Graf R; Bond GL; Grochola LF
    Clin Cancer Res; 2016 Dec; 22(24):6069-6077. PubMed ID: 27283965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
    Yin JB; Li N; Cui MM; Wang X; Wang RT
    BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.
    Stratford JK; Bentrem DJ; Anderson JM; Fan C; Volmar KA; Marron JS; Routh ED; Caskey LS; Samuel JC; Der CJ; Thorne LB; Calvo BF; Kim HJ; Talamonti MS; Iacobuzio-Donahue CA; Hollingsworth MA; Perou CM; Yeh JJ
    PLoS Med; 2010 Jul; 7(7):e1000307. PubMed ID: 20644708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma.
    Li G; Chen JZ; Chen S; Lin SZ; Pan W; Meng ZW; Cai XR; Chen YL
    Cancer Med; 2020 May; 9(10):3353-3370. PubMed ID: 32181599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
    Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
    Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients.
    Paiella S; Malleo G; Cataldo I; Gasparini C; De Pastena M; De Marchi G; Marchegiani G; Rusev B; Scarpa A; Girelli R; Giardino A; Frigerio I; D'Onofrio M; Secchettin E; Bassi C; Salvia R
    Langenbecks Arch Surg; 2018 Mar; 403(2):213-220. PubMed ID: 28983662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy.
    Markus M; Abendroth A; Noureddine R; Paul A; Breitenbuecher S; Virchow I; Schmid KW; Markus P; Schumacher B; Wiesweg M; Wendling J; Mende B; Siveke JT; Schuler M; Kasper S
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):579-591. PubMed ID: 32839836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic Testing for Gemcitabine-Based Treatment of Pancreatic Cancer.
    Zhang J; Hochwald SN
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857393
    [No Abstract]   [Full Text] [Related]  

  • 39. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
    Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
    HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.